Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Targacept

Powering Rapid Cognitive Analysis with AI

Dr. Tom Sawyer, CFO at Cognetivity Neurosciences, discusses the benefits of AI-driven dementia detection technology for patients, health care providers, and clinical research.

Impetus Digital

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer’s disease

Eisai presented the data at the Alzheimer’s Association International Conference (AAIC)

- PMLiVE

Alzheimer’s Research UK calls for government action to address inequalities in dementia risk

The call comes as researchers presented findings demonstrating a link between socio-economic deprivation and higher dementia risk

- PMLiVE

Alzheimer’s Research UK welcomes ambitions for dementia set out in first women’s health strategy

The ten-year strategy follows the charity’s calls for action to tackle dementia’s disproportionate impact on women

- PMLiVE

Roche’s diagnostic test for Alzheimer’s receives FDA Breakthrough Device Designation

Alzheimer's affects more than 55 million people globally and is the most common form of dementia

- PMLiVE

FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease

Lecanmab is being evaluated in the ongoing phase 3 Clarity Alzheimer's clinical trial

- PMLiVE

Alzheimer’s Research UK supports government plans for clinical research

The charity has suggested creating a Dementia Medicines Taskforce in order to address diseases like Alzheimer's

- PMLiVE

Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease

The new approach would allow doctors to identify the disease at an early stage and provide treatment and support to patients sooner

- PMLiVE

LifeArc partners with UK Dementia Research Institute

Dementia affects around 900,000 people in the UK and this is expected to rise to around 1.6 million by 2040

- PMLiVE

TauRx shares phase 3 trial data for Alzheimer’s drug

Those receiving the drug experienced a significantly slower decline than usual

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links